We are international
Donate
TEXT SIZE   


Expanded Access Program Opens for Daratumumab
07.17.15

Janssen Biotech, Inc. has announced the opening of a daratumumab expanded access program (EAP) at up to 40 medical centers for eligible US myeloma patients who have received at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent) or are double refractory to a proteasome inhibitor and an immunomodulatory agent. Daratumumab is currently an investigational human anti-CD38 monoclonal antibody treatment for multiple myeloma. To learn more about the EAP for daratumumab, contact the IMF InfoLine at (800) 452-2873 or email infoline@myeloma.org.


 related articles